BioAtla Faces Delisting Concerns

TL;DR

BioAtla's stock might be delisted due to listing rule violations.

AI Summary

BioAtla, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective February 6, 2025. The company is based in San Diego, California, and operates in the biological products sector.

Why It Matters

This filing indicates potential issues with BioAtla's continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's market presence and investor confidence.

Key Players & Entities

• BioAtla, Inc. (company) — Registrant
• February 06, 2025 (date) — Date of earliest event reported
• February 07, 2025 (date) — Filing date
• San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Glo
• $1.00 — the Company's common stock of at least $1.00 per share for the last 30 consecutive b

Filing Documents

• bcab-20250206.htm (8-K) — 42KB
• 0000950170-25-016321.txt ( ) — 150KB
• bcab-20250206.xsd (EX-101.SCH) — 23KB
• bcab-20250206_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Nasdaq Bid Price Deficiency Letter On February 6, 2025, BioAtla, Inc. (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Rule") because the Company has not maintained a minimum closing bid price of the Company's common stock of at least $1.00 per share for the last 30 consecutive business days. The Notice has no immediate effect on the listing or trading of the Company's securities. The Company has 180 calendar days from the date of the Notice, or until August 5, 2025, to regain compliance. If the Company is not deemed in compliance before the expiration of the 180-day compliance period, it will be afforded an additional 180-day compliance period, provided that the Company transfers to The Nasdaq Capital Market and it meets the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on The Nasdaq Capital Market (except for the Rule) based on the Company's most recent public filings and market information and provides written notice to Nasdaq of its intention to cure this deficiency during the second compliance period. Compliance can be achieved during any compliance period by meeting the applicable standard for a minimum of ten (10) consecutive business days during the applicable compliance period, unless Nasdaq exercises its discretion to extend this 10-day period as discussed in Rule 5810(c)(3)(H). If the Company does not regain compliance with the Rule within the applicable compliance period, the Company's common stock will be subject to delisting. In the event the Company receives notice that the Company's common stock is being delisted, Nasdaq's rules permit the Company to appeal the delis

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: February 7, 2025 By: /s/ Richard A. Waldron Richard A. Waldron Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR